Karyopharm Therapeutics Inc. Basic Shares Outstanding (Weighted Average)
Karyopharm Therapeutics Inc. (KPTI) reported Basic Shares Outstanding (Weighted Average) of 28.94 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-13
- Karyopharm Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 28.94K shares, a 235.71% increase year-over-year.
- Karyopharm Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 22.01K shares, a 159.91% increase year-over-year.
- Karyopharm Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 17.98K shares, a 114.24% increase year-over-year.
- Karyopharm Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 8.67K shares, a 3.99% increase year-over-year.
- Karyopharm Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 10.94K shares, a 34.58% increase from fiscal 2024.
- Karyopharm Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 8.13K shares, a 6.68% increase from fiscal 2023.
- Karyopharm Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 7.62K shares, a 90.70% decline from fiscal 2022.
- Karyopharm Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 81.87K shares, a 99.89% decline from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic 12 month | Weighted Average Number of Shares Outstanding, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 28.94K shares 10-Q · filed 2026-08-13 | 25.50K shares 10-Q · filed 2026-08-13 | 22.98K shares derived: average of 3 quarters · filed 2026-08-13 | 19.40K shares derived: average of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | 22.01K shares 10-Q · filed 2026-05-14 | 20.00K shares derived: average of 2 quarters · filed 2026-05-14 | 16.22K shares derived: average of 3 quarters · filed 2026-05-14 | 14.32K shares derived: average of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | 17.98K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | 13.32K shares derived: average of 2 quarters · filed 2026-02-13 | 11.76K shares derived: average of 3 quarters · filed 2026-08-13 | 10.94K shares 10-K · filed 2026-02-13 | ||||
| 2025-09-30 | 8.67K shares 10-Q · filed 2025-11-03 | 8.64K shares derived: average of 2 quarters · filed 2026-08-13 | 8.59K shares 10-Q · filed 2025-11-03 | 8.54K shares derived: average of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | 8.62K shares 10-Q · filed 2026-08-13 | 8.54K shares 10-Q · filed 2026-08-13 | 8.49K shares derived: average of 3 quarters · filed 2026-08-13 | 8.45K shares derived: average of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | 8.47K shares 10-Q · filed 2026-05-14 | 8.43K shares derived: average of 2 quarters · filed 2026-05-14 | 8.40K shares derived: average of 3 quarters · filed 2026-05-14 | 8.32K shares derived: average of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | 8.39K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | 8.36K shares derived: average of 2 quarters · filed 2026-02-13 | 8.27K shares derived: average of 3 quarters · filed 2026-02-13 | 8.13K shares 10-K · filed 2026-02-13 | 121.86K shares 10-K · filed 2025-02-19 | |||
| 2024-09-30 | 8.34K shares 10-Q · filed 2025-11-03 | 125.01K shares 10-Q · filed 2024-11-05 | 8.20K shares derived: average of 2 quarters · filed 2025-11-03 | 8.04K shares 10-Q · filed 2025-11-03 | 120.51K shares 10-Q · filed 2024-11-05 | -71.88K shares derived: average of 4 quarters · filed 2026-02-13 | ||
| 2024-06-30 | 8.07K shares 10-Q · filed 2025-08-11 | 121.03M shares 10-Q · filed 2024-08-06 | 7.88K shares 10-Q · filed 2025-08-11 | 118.24M shares 10-Q · filed 2024-08-06 | -98.62K shares derived: average of 3 quarters · filed 2026-02-13 | -45.37K shares derived: average of 4 quarters · filed 2026-02-13 | ||
| 2024-03-31 | 7.70K shares 10-Q · filed 2025-05-12 | 115.45M shares 10-Q · filed 2024-05-08 | -151.97K shares derived: average of 2 quarters · filed 2026-02-13 | -63.18K shares derived: average of 3 quarters · filed 2026-02-13 | 28.50M shares derived: average of 4 quarters · filed 2026-02-13 | |||
| 2023-12-31 | -311.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -98.62K shares derived: average of 2 quarters · filed 2026-02-13 | 38.00M shares derived: average of 3 quarters · filed 2026-02-13 | 7.62K shares 10-K · filed 2026-02-13 | 114.22M shares 10-K · filed 2024-02-29 | |||
| 2023-09-30 | 114.40K shares 10-Q · filed 2024-11-05 | 114.40M shares 10-Q · filed 2023-11-02 | 57.16M shares derived: average of 2 quarters · filed 2024-11-05 | 114.03K shares 10-Q · filed 2024-11-05 | 114.03M shares 10-Q · filed 2023-11-02 | -2.33M shares derived: average of 4 quarters · filed 2025-02-19 | ||
| 2023-06-30 | 114.21M shares 10-Q · filed 2024-08-06 | 113.85M shares 10-Q · filed 2024-08-06 | -3.15M shares derived: average of 3 quarters · filed 2025-02-19 | 17.69M shares derived: average of 4 quarters · filed 2025-02-19 | ||||
| 2023-03-31 | 113.48M shares 10-Q · filed 2024-05-08 | -61.83M shares derived: average of 2 quarters · filed 2025-02-19 | -14.48M shares derived: average of 3 quarters · filed 2025-02-19 | 9.05M shares derived: average of 4 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | -237.13M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -78.46M shares derived: average of 2 quarters · filed 2025-02-19 | -25.76M shares derived: average of 3 quarters · filed 2025-02-19 | 81.87K shares 10-K · filed 2025-02-19 | 81.87M shares 10-K · filed 2023-02-17 | |||
| 2022-09-30 | 80.21M shares 10-Q · filed 2023-11-02 | 79.93M shares derived: average of 2 quarters · filed 2023-11-02 | 79.15M shares 10-Q · filed 2023-11-02 | 78.28M shares derived: average of 4 quarters · filed 2024-02-29 | ||||
| 2022-06-30 | 79.65M shares 10-Q · filed 2023-08-02 | 78.62M shares 10-Q · filed 2023-08-02 | 77.63M shares derived: average of 3 quarters · filed 2024-02-29 | 77.09M shares derived: average of 4 quarters · filed 2024-02-29 | ||||
| 2022-03-31 | 77.57M shares 10-Q · filed 2023-05-04 | 76.62M shares derived: average of 2 quarters · filed 2024-02-29 | 76.24M shares derived: average of 3 quarters · filed 2024-02-29 | 75.97M shares derived: average of 4 quarters · filed 2024-02-29 | ||||
| 2021-12-31 | 75.68M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 75.57M shares derived: average of 2 quarters · filed 2024-02-29 | 75.44M shares derived: average of 3 quarters · filed 2024-02-29 | 75.22M shares 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | 75.46M shares 10-Q · filed 2022-11-03 | 75.33M shares derived: average of 2 quarters · filed 2022-11-03 | 75.06M shares 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | 75.19M shares 10-Q · filed 2022-08-04 | 74.86M shares 10-Q · filed 2022-08-04 | ||||||
| 2020-12-31 | 72.04M shares 10-K · filed 2023-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |